权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PD-1/PD-L1 modulation in cancer therapy

癌症治疗中的 PD-1/PD-L1 调节

基本信息

批准号：
9188057
负责人：
DREW M. PARDOLL
金额：
$ 48.83万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-06-21 至 2020-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9188057
关键词：
Antigens Automobile Driving Autopsy B7-DC antigen Biological Biological Markers Blocking Antibodies Cells Clinical Combined Modality Therapy Common Neoplasm Development Disease Epigenetic Process Funding Genetic Grant Head Cancer Hodgkin Disease Human Immune Immune response Immune system Immunity Immunologics Immunotherapy In Situ Hybridization In Vitro Interferon Type II Knowledge Lesion Ligands Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of ovary Malignant neoplasm of urinary bladder Membrane Molecular Mus Neck Cancer Neoplasm Metastasis Outcome PDCD1LG1 gene Pathway interactions Patients Pharmaceutical Preparations Pharmacologic Substance Phase Phosphorylation Process Regulation Regulatory T-Lymphocyte Renal carcinoma Resistance Resistance development Role Signal Pathway Signal Transduction Signaling Molecule Solid Neoplasm Specimen System T-Lymphocyte Testing Thinking Tissues Transforming Growth Factor beta Tumor-Infiltrating Lymphocytes Up-Regulation Ursidae Family base biomarker development biomarker-driven cancer cell cancer immunotherapy cancer therapy cell type clinical application clinical development clinical effect clinical practice combinatorial cytokine digital human tissue immune resistance immunological diversity in vivo in vivo Model individual patient innovation melanoma mouse model neoplastic cell overexpression predicting response programs promoter public health relevance receptor research clinical testing resistance mechanism responders and non-responders response spectrograph tumor tumor growth tumor microenvironment tumor progression

项目摘要

DESCRIPTION (provided by applicant): Over the past 10 years, studies of the immune microenvironment of cancer in both murine models and in humans has identified intracellular signaling pathways and expression of membrane ligands and receptors that locally inhibit antitumor immune responses. Among the most important are the ligands PD-L1 and PD-L2 that interact with the co-inhibitory receptor PD-1 on activated T cells. PD-1 pathway-blocking antibodies have so far had significant impact in melanoma, renal, lung, bladder, head and neck, and ovarian cancers, and Hodgkin's lymphoma. During the initial R01 funding period, we have made major discoveries regarding regulation of the expression of PD-1 and its ligands, that have important implications for identifying biomarkers and developing combinatorial approaches to cancer immunotherapy. Specifically, we showed that PD-L1 expression in tumors predicts response to PD-1 blockade. This finding has led to the development of PD-L1 IHC tests by several major pharmaceutical companies developing PD-1 pathway blocking drugs. We also demonstrated coordinate expression of PD-L1 and other checkpoint molecules, supporting the clinical development of the anti-PD-1/LAG-3 combination. Finally, we developed major biological and molecular concepts for understanding regulation of PD-1 and its ligands in the tumor microenvironment (TME), namely that expression represents a dynamic cross- talk between tumor cells and TILs. We showed that a dominant mechanism for PD-L1 up-regulation on certain tumors is not constitutive induction but rather adaptive resistance, whereby tumors respond to "sensing" of immune threat through IFN-g. The adaptive resistance concept now guides thinking in the field. Conversely, we also showed that a major cytokine produced by tumor cells, TGF-b, can enhance TCR-driven PD-1 promoter activity and thus PD-1 expression on T cells. These discoveries from our previous grant period raise a number of additional questions that bear on advances in immunotherapy: Why do some tumor types express PD-L1 adaptively and others constitutively? What are the relative functional roles of PD-L1 expression by tumor cells vs. infiltrating immune cells? Is the expression of PD-1 on TILs regulated in vivo by levels of TGF-b and TGF-b dependent signaling molecules? How heterogeneous is expression of PD-1, PD-L1 and other coordinately regulated checkpoint molecules among metastases in a given patient? Why do many patients with PD-L1+ tumors NOT respond to PD-1 pathway blockers? To answer these questions, we propose three Aims in this competing renewal: 1) Define mechanisms regulating PD-L1 expression by tumor cells and other cell types in the TME; 2) Characterize factors influencing PD-1 expression by T cells; and 3) Characterize immunological mechanisms underlying the clinical effects of PD-L1/PD-1 blockade in cancer therapy, including the co-expression of multiple checkpoint pathways that might provide resistance pathways to therapy.